Literature DB >> 10361620

Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review.

K Weaver1, A Glasier.   

Abstract

There is considerable variation in opinion about the importance of drug interactions between the combined oral contraceptive pill (COCP) and broad-spectrum antibiotics. Clinical practice varies widely, especially between doctors in Europe and those in the US. Rifampicin and griseofulvin induce hepatic enzymes and do appear to have a genuine interaction with the COCP, leading to reduced efficacy. The situation with the broad-spectrum antibiotics is less clear. There are relatively few prospective studies of the pharmacokinetics of concurrent COCP and antibiotic use and few, if any, demonstrate a convincing basis for any reduced contraceptive efficacy. There is evidence, however, that variable contraceptive steroid handling could make some women, at some times, more susceptible to COCP failure. Given the serious consequences of unwanted pregnancy, the cautious approach of using additional or alternative contraception during short courses of broad-spectrum antibiotics and the initial weeks of long-term antibiotic administration may be justified to safeguard the few unidentifiable women who may be at risk. Conflicting opinion and advice is potentially confusing to both professionals and patients, and instructions for additional precautions during and after concurrent COCP and antibiotic use are complicated. Many women are ignorant of, or confused about, the circumstances that can cause OC to fail. Health professionals who prescribe the COCP must continue to strive to educate women about the mode of action and about the times when there is the greatest danger of failure. Professionals who feel that concurrent antibiotic use represents a real threat to contraceptive efficacy of the COCP should be prepared to present the advice for additional contraceptive precautions in a simple and consistent way, backed up with written information and reinforced at regular intervals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361620     DOI: 10.1016/s0010-7824(99)00009-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  How safe is emergency contraception?

Authors:  Abigail Norris Turner; Charlotte Ellertson
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.

Authors:  Peter Dogterom; Michiel W van den Heuvel; Torben Thomsen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Examining the use of oral contraceptives in the management of acne.

Authors:  Heather L Salvaggio; Andrea L Zaenglein
Journal:  Int J Womens Health       Date:  2010-08-09

Review 4.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.

Authors:  Kazuto Yasuda; Aarati Ranade; Raman Venkataramanan; Stephen Strom; Jonathan Chupka; Sean Ekins; Erin Schuetz; Kenneth Bachmann
Journal:  Drug Metab Dispos       Date:  2008-05-27       Impact factor: 3.922

6.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Authors:  Tore Bjerregaard Stage; Magnus Graff; Susan Wong; Louise Ladebo Rasmussen; Flemming Nielsen; Anton Pottegård; Kim Brøsen; Deanna L Kroetz; S Cyrus Khojasteh; Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.